Can a diabetes drug protect transplanted kidneys? new study aims to find out
NCT ID NCT06013865
First seen Apr 22, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This study is testing whether empagliflozin (Jardiance), a drug used for diabetes and chronic kidney disease, is safe for people who have received a kidney transplant. Researchers will enroll 264 veterans and monitor for side effects like infections and changes in kidney function. If safe, it could help prevent heart and kidney problems in transplant recipients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Edward Hines Jr. VA Hospital, Hines, IL
RECRUITINGHines, Illinois, 60141-3030, United States
Contact Email: •••••@•••••
-
Iowa City VA Health Care System, Iowa City, IA
RECRUITINGIowa City, Iowa, 52246-2292, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
RECRUITINGOmaha, Nebraska, 68105-1850, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN
RECRUITINGNashville, Tennessee, 37212-2637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
RECRUITINGPittsburgh, Pennsylvania, 15240, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empagliflozin (Jardiance)
What this could lead to
If successful, this could show that empagliflozin is safe for kidney transplant patients, potentially reducing heart and kidney complications.
What could go wrong
This is a small, early-phase safety study, so results may not confirm effectiveness. There are concerns about increased infections and effects on graft function.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.